Cost effectiveness of three months of rifapentine and isoniazid for latent tuberculosis in Syrian refugees.

ABSTRACT:

Background

Latent Tuberculosis infection (LTBI) has a large global burden especially among refugees. We aimed to test the cost effectiveness of weekly rifapentine plus isoniazid for 3 months (3HP) versus nine months of daily isoniazid (INH-9) to treat LTBI in Syrian refugees residing in Turkey.

Methods

We used a Markov state transition model to estimate the incremental cost-effectiveness of 3HP relative to INH-9 using a simulated cohort of Syrian refugees. Both cost and effectiveness were assessed assuming that LTBI screening would be performed, with treatment of those who screen positive. Costs were measured in 2017 US dollars, and effectiveness was estimated as quality adjusted life years (QALYs) gained. An annual discount rate of 3% was applied to future costs and QALYs o

SUBMITTER: Ilaiwy G 

PROVIDER: S-EPMC8326807 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature